Cardiovascular Systems (CSI) recently announced that it has made significant progress towards the commercialization of its intravascular lithotripsy (IVL) system for the treatment of calcific peripheral arterial disease (PAD).
A company press release notes that feasibility testing of a proprietary console and associated IVL balloon catheters is complete. The company’s IVL systems are designed to improve upon the limitations of incumbent technology, the release details, allowing physicians to cross and treat more challenging atherosclerotic lesions. CSI is also developing IVL technology to treat coronary artery disease (CAD).
Cardiovascular Systems’ peripheral orbital atherectomy devices are primarily used by physicians to treat long, diffuse calcified arteries below the knee. Introducing a peripheral IVL system to the company’s offering will expand its treatable patient population across an even broader spectrum of calcified arteries above and below the knee, the press release states. The company plans to begin first-in-human experience for the peripheral IVL system in calendar 2023.
